Dr. Tomoaki Hinohara serves as a member of TransMed7’s Clinicial and Scientific Advisory Board.
Dr. Hinohara was born in Tokyo, Japan and graduated from Keio University in Tokyo. He completed his postgraduate training in Internal Medicine and Cardiology at McGill University in Montreal, Canada. Following these training years, he completed his Cardiology Fellowship while becoming the first Interventional Cardiovascular Fellow at Duke University Medical Center in Durham, North Carolina. He then served as Director of the Interventional Laboratory at Duke University Medical Center from 1986 to1988.
In 1988 Dr. Hinohara joined Cardiovascular Medicine and Coronary Interventions (CMCI) founded by Doctor/Professor John B. Simpson, becoming a full partner in the group. CMCI was formed in the San Francisco Bay area to serve cardiovascular patients at Sequoia Hospital in Redwood City and Stanford University Hospitals in Palo Alto. As a member of the “Simpson Group” Dr. Hinohara helped pioneer and advance many techniques in cardiovascular interventions and served as a Consultant for Devices for Vascular Intervention (DVI), which was also founded by Dr. Simpson and later folded into Guidant, Inc. Dr. Hinohara became a prodigious scientific writer and highly respected lecturer while deeply involved in a wide variety of clinical testing, device/technique development, and the FDA clearance process for a new platform of vascular interventional devices. He also founded and served as a leader of the Cardiovascular Research Foundation, contributing many scientific abstracts and manuscripts that significantly advanced the worldwide understanding of fundamental cardiovascular disease processes as well as the effectiveness of a variety of ground-breaking therapeutic interventions.
After his role with DVI, Dr. Hinohara became a Co-Founder of and Board of Directors Member for Perclose, Inc., which, after undergoing a successful IPO and market ramp was subsequently acquired by Abbott Laboratories in November 1999.
After the Perclose acquisition, Dr. Hinohara co-founded and served as a Member of the Board of Directors of FoxHollow Technologies, Inc. FoxHollow (FHT) specialized in the design, manufacture, and sales of medical devices primarily for the treatment of peripheral artery disease (PAD). After a successful IPO and high performance in the marketplace, FoxHollow was ultimately acquired in 2007 by Covidien, which later merged with Medtronic, Inc.
Dr. Hinohara is a world-renowned interventional cardiologist and vascular interventionist, currently serving as Director of the Catheterization Lab at Sequoia Hospital in Redwood City, California. He continues to specialize in complex coronary and peripheral vascular interventional procedures.